Free Trial

Genus (LON:GNS) Posts Earnings Results

Genus logo with Medical background

Key Points

  • Genus reported quarterly earnings of GBX 81.80 per share, with a return on equity of 1.41% and a net margin of 1.18%.
  • The company's shares opened at GBX 2,816.40, with a market capitalization of £1.85 billion and a current ratio of 1.80.
  • Recent analyst ratings include a "buy" from Shore Capital with a price target of GBX 2,900, and Deutsche Bank raised their target to GBX 2,550.
  • MarketBeat previews the top five stocks to own by October 1st.

Genus (LON:GNS - Get Free Report) posted its earnings results on Thursday. The company reported GBX 81.80 earnings per share for the quarter, Digital Look Earnings reports. Genus had a return on equity of 1.41% and a net margin of 1.18%.

Genus Stock Performance

LON:GNS traded down GBX 15 during trading hours on Monday, reaching GBX 2,670. The company had a trading volume of 80,418 shares, compared to its average volume of 259,989. The firm has a market cap of £1.75 billion, a price-to-earnings ratio of -43,064.52, a PEG ratio of 2.87 and a beta of 0.37. The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12. The firm's 50 day moving average price is GBX 2,451.67 and its 200-day moving average price is GBX 2,086.52. Genus has a 52 week low of GBX 1,424 and a 52 week high of GBX 3,228.80.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Shore Capital restated a "buy" rating and issued a GBX 2,900 price objective on shares of Genus in a research report on Thursday. Deutsche Bank Aktiengesellschaft increased their target price on shares of Genus from GBX 2,250 to GBX 2,550 and gave the stock a "buy" rating in a research note on Tuesday, July 15th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Genus presently has a consensus rating of "Buy" and an average price target of GBX 2,725.

View Our Latest Report on GNS

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Read More

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.